Tandem Diabetes Care, Inc.TNDMNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts are neutral — opinion is divided on direction.

Consensus Rating

Hold

25 analysts·High coverage

44%

Rating Distribution

Strong Buy

00%

Buy

1144%

Hold

1352%

Sell

14%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see moderate upside — consensus target 25% higher.

Bear Case

$14.00

-30%

Consensus

$24.89

+25%

Bull Case

$35.00

+76%

Price Range25 analysts

Low

Consensus

High

$14.00

$35.00

Current Target

Current Price

$19.89

Upside to Target

$5.00

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-0.92(14 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+9.12%

EPS—

FY2028

Rev+9.49%

EPS—

FY2029

Rev+6.49%

EPS+126.01%

Earnings Surprises

Beat rate:33%(4/12 quarters)

Avg surprise:-32.5%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Jan 9, 2026Goldman Sachs

Tandem Diabetes price target raised to $25 from $16 at Goldman Sachs

Target:$25.00

+11.1%from $22.50

Dec 18, 2025Truist Financial

Tandem Diabetes price target raised to $24 from $17 at Truist

Target:$24.00

+8.0%from $22.22

Dec 17, 2025RBC Capital

Tandem Diabetes price target raised to $30 from $25 at RBC Capital

Target:$30.00

+31.5%from $22.81

Dec 17, 2025Canaccord Genuity

Tandem Diabetes price target raised to $35 from $24 at Canaccord

Target:$35.00

+54.9%from $22.60

Dec 17, 2025Mizuho Securities

Tandem Diabetes price target raised to $21 from $18 at Mizuho

Target:$21.00

-7.1%from $22.60

Dec 16, 2025Robert W. Baird

Tandem Diabetes upgraded to Outperform from Neutral at Baird

Target:$30.00

+35.6%from $22.12

Dec 2, 2025Morgan Stanley

Tandem Diabetes price target raised to $23 from $17 at Morgan Stanley

Target:$23.00

+12.1%from $20.51

Oct 15, 2025Truist Financial

Tandem Diabetes price target raised to $16 from $14 at Truist

Target:$16.00

+5.9%from $15.11

Sep 8, 2025Oppenheimer

Tandem Diabetes assumed with an Outperform at Oppenheimer

Target:$22.00

+76.0%from $12.50

Aug 7, 2025Canaccord Genuity

Tandem Diabetes price target lowered to $24 from $59 at Canaccord

Target:$24.00

+114.4%from $11.20

Aug 7, 2025Piper Sandler

Tandem Diabetes downgraded to Neutral from Overweight at Piper Sandler

Target:$14.00

-2.7%from $14.39

Mar 5, 2025Morgan Stanley

Tandem Diabetes downgraded to Equal Weight from Overweight at Morgan Stanley

Target:$22.00

+15.1%from $19.11

Feb 28, 2025Bernstein

Tandem Diabetes downgraded to Market Perform from Outperform at Bernstein

Target:$25.00

+12.9%from $22.14

Feb 28, 2025Barclays

Tandem Diabetes price target lowered to $53 from $60 at Barclays

Target:$53.00

+139.4%from $22.14

Jan 8, 2025Bernstein

Tandem Diabetes price target raised to $44 from $42 at Bernstein

Target:$44.00

+17.4%from $37.49

Nov 7, 2024Robert W. Baird

Tandem Diabetes Care (TNDM) PT Lowered to $37 at Baird

Target:$37.00

+12.6%from $32.87

Nov 5, 2024Bernstein

Bernstein SocGen Group Starts Tandem Diabetes Care (TNDM) at Outperform

Target:$42.00

+26.8%from $33.11

Oct 4, 2024Goldman Sachs

This MINISO Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Target:$46.00

+15.0%from $39.99

Oct 2, 2024RBC Capital

Tandem Diabetes initiated with an Outperform at RBC Capital

Target:$65.00

+58.3%from $41.07

Aug 8, 2024Canaccord Genuity

Tandem Diabetes initiated with a Buy at Canaccord

Target:$57.00

+53.9%from $37.04

Aug 5, 2024Barclays

Tandem Diabetes price target raised to $58 from $55 at Barclays

Target:$58.00

+39.2%from $41.67

Aug 2, 2024Piper Sandler

Tandem Diabetes price target raised to $55 from $50 at Piper Sandler

Target:$55.00

+56.2%from $35.21

Aug 2, 2024Robert W. Baird

Tandem Diabetes price target raised to $39 from $36 at Baird

Target:$39.00

+10.8%from $35.21

Jun 10, 2024Oppenheimer

Tandem Diabetes Care (TNDM) PT Raised to $58 at Oppenheimer

Target:$58.00

+23.3%from $47.03

May 29, 2024Stifel Nicolaus

Tandem Diabetes Care (TNDM) PT Raised to $60 at Stifel

Target:$60.00

+15.5%from $51.93

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance